醫思健康(02138.HK)：預計年度銷售額不少於30億港元，同比升幅不少於35%
格隆匯4月21日丨醫思健康(02138.HK)發佈公吿，截至2022年3月31日止年度，集團預期錄得期內銷售額將不少於30億港元，較去年同期升幅不少於35%；集團中國香港所提供的醫療服務銷售額期內下半年較去年同期增長不少於25%及期內較去年同期增長不少於55%；集團中國香港及中國澳門所提供的醫學美容及美容服務期內下半年較去年同期增長不少於5%及期內較去年同期增長不少於15%；及中國內地診所以及服務中心的期內銷售額期內下半年較去年同期增長不少於8%及期內較去年同期增長不少於18%。
公吿表示，儘管第五波本地新型冠狀病毒疾病爆發引致持續的旅遊限制，社交距離收緊及中國香港所有美容院於2022年1月的另一輪強制關閉對整體經濟造成不利影響，集團下半年的整體銷售表現仍取得了超過15%的同比增長。在強制關閉的104個工作日內，集團能夠主動與客户透過線上渠道及電子商務活動保持互動，以促進本地市場和中國內地的銷售；促進不同醫療專科的間的交叉銷售；積極拓展新型冠狀病毒相關醫療服務；及完成了對若干醫療機構的收購。董事會認為，隨着中國香港政府於2022年4月21日放寬預防新型冠狀病毒措施後業務重新開放，強勁的需求將使集團受益。
展望未來，集團對其業務表現持樂觀態度，預期將受益於近期政府推出電子消費券計劃帶動下的本地零售市場復甦對新型冠狀病毒相關醫療服務，包括但不僅限於身體檢查，核酸測試及抗體檢測的持續需求；新型冠狀病毒疫苗接種及外展服務的持續需求；遠程醫療服務的普及和需求提升；及市場的持續整合。集團將繼續全力支持及配合中國香港政府的新型冠狀病毒抗疫政策，積極採取措施，推行新策略以把握商機，持續擴大其醫療服務範圍，並將繼續通過內生增長和收購合併來發展業務，特別聚焦於資訊科技，品牌和服務，進而增加集團的市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
